OraSure Technologies (OraSure Technologies) Debt-to-Equity : 0.03 (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is OraSure Technologies Debt-to-Equity?

OraSure Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.1 Mil. OraSure Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11.4 Mil. OraSure Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $430.7 Mil. OraSure Technologies's debt to equity for the quarter that ended in Dec. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for OraSure Technologies's Debt-to-Equity or its related term are showing as below:

OSUR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.03 Max: 0.03
Current: 0.03

During the past 13 years, the highest Debt-to-Equity Ratio of OraSure Technologies was 0.03. The lowest was 0.02. And the median was 0.03.

OSUR's Debt-to-Equity is ranked better than
87.5% of 712 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs OSUR: 0.03

OraSure Technologies Debt-to-Equity Historical Data

The historical data trend for OraSure Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OraSure Technologies Debt-to-Equity Chart

OraSure Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.03

OraSure Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.03	0.03	0.04	0.04	0.03

Competitive Comparison of OraSure Technologies's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, OraSure Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OraSure Technologies's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OraSure Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where OraSure Technologies's Debt-to-Equity falls into.

OraSure Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

OraSure Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.116	+	11.388)	/	430.671
	=	0.03

OraSure Technologies's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.116	+	11.388)	/	430.671
	=	0.03

OraSure Technologies (NAS:OSUR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

OraSure Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of OraSure Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

OraSure Technologies (OraSure Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OraSure Technologies Inc (NAS:OSUR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

EP3:Germany

Address

220 East First Street, Bethlehem, PA, USA, 18015

Website

https://www.orasure.com

OraSure Technologies is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets most of its sales from the molecular solutions business, derived mainly from customers in the United States.

Executives

Kathleen Gallagher Weber	officer: Chief Product Officer	220 EAST FIRST STREET, BETHLEHEM PA 18017
Michele Marie Miller	officer: VP, Finance and Controller	220 EAST FIRST STREET, BETHLEHEM PA 18017
Robert W. Mcmahon	director	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kenneth J Mcgrath	officer: Chief Financial Officer	C/O ORASURE TECHNOLOGIES, INC., 220 E. FIRST STREET, BETHLEHEM PA 18015
Ronny B Lancaster	director	ORASURE TECHNOLOGIES INC, 220 EAST FIRST STREET, BETHLEHEM PA 18015
Mara G. Aspinall	director	7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Nancy J Gagliano	director	33 GRANITE WAY, GRANTHAM NH 03753
Michael Celano	director	220 EAST FIRST STREET, BETHLEHEM PA 18015
Manner Carrie Eglinton	director, officer: President & CEO	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Scott Gleason	officer: Interim CFO/SVP IR	1809 SOUTH 2500 EAST, SALT LAKE CITY UT 84108
Eamonn P Hobbs	director	C/O DELCATH SYSTEMS, INC., 600 FIFTH AVENUE, NEW YORK NY 10020
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James A Datin	director	21 ESTATES DRIVE, DOYLESTOWN PA 18901
Lelio Marmora	director	64 RUE DE VESENEX, DIVONNE LES BAINS I0 01220
Lisa Nibauer	officer: President of Diagnostics	1 CRESENT PLACE, SHORT HILLS NJ 07078